1977. Comparative Effectiveness of Linezolid vs. Trimethoprim-Sulfamethoxazole for Acute Bacterial Skin and Skin Structure Infections (ABSSSIs) at a Veterans Affairs Hospital
Session: Poster Abstract Session: Clinical Trials
Saturday, October 6, 2018
Room: S Poster Hall

Linezolid (LZD) and trimethoprim-sulfamethoxazole (TMP-SMX) are both used in the treatment of acute bacterial skin and skin structure infection (ABSSSI) with differing adverse event profiles to guide usage, but their comparative efficacies in severe ABSSSI remain unclear.


This retrospective cohort study evaluated patients admitted to the VA St. Louis Health Care System for treatment of an ABSSSI between 04/18/2000 and 10/16/2017 and discharged with a prescription for ≥5 days of LZD or TMP-SMX. The primary outcome was clinical failure, defined as a composite of an Emergency Department visit, clinic visit, inpatient admission, extension of antibiotics, change of antibiotic regimen for any reason, or the presence of an adverse reaction occurring in the 14 days after completion of the outpatient regimen. Adverse reactions evaluated were acute kidney injury, hyperkalemia, neutropenia, thrombocytopenia, and anemia. The secondary outcome evaluated risk factors for clinical failure with multivariate logistic regression analysis. Potential factors to be included in the analysis were drug choice, duration of intravenous antibiotic use while inpatient (<24 hours, ≥24 hours to ≤48 hours, >48 hours), identification of methicillin-resistant Staphylococcus aureus (MRSA) in culture, MRSA nasal colonization, and incision and drainage.


A total of 139 patients were included in the analysis; 51 treated with LZD and 88 treated with TMP-SMX. Length of hospital stay was greater in the LZD group (6.05 days vs. 3.69 days [P=0.023]), as was antibiotic use during hospitalization (98% [49/50] vs. 86% [77/90]; P=0.019). The mean day supply of antibiotic dispensed at discharge was 10.18 in the LZD group and 9.64 in the TMP-SMX group (P=0.48). Twenty-two percent (11/51) of patients treated with LZD and 18% (16/88) of those treated with TMP-SMX (P=0.878) experienced clinical failure. Only receipt of antibiotics for 24-48 hours during hospitalization met criteria for inclusion in the multivariate analysis, but was not significantly associated with clinical failure (0.367 [95% CI 0.083-1.63]; P=0.187).


There was no difference in the rate of clinical failure between patients treated with LZD or TMP-SMX for severe ABSSSI.

Xing Tan, Pharm.D., Pharmacy, VA St. Louis Health Care System, St. Louis, MO, Travis W. Linneman, Pharm.D., Pharmacy Services/Medicine Specialty Care, St. Louis VA Medical Center - John Cochran Division, St. Louis, MO and Ryan P. Moenster, Pharm.D., FIDSA, Pharmacy Practice, St. Louis College of Pharmacy, Saint Louis, MO; Pharmacy Services, VA Saint Louis Health Care System, Saint Louis, MO


X. Tan, None

T. W. Linneman, None

R. P. Moenster, None

See more of: Clinical Trials
See more of: Poster Abstract Session

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.